{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9"},{"groupId":"OG001","value":"39.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do).HAQ-DI=sum of worst scores in each domain divided by the number of domains answered.","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Re-treatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Re-treatment"}],"paramType":"NUMBER","populationDescription":"Participants from the Intent-to-treat population, that includes all participants randomized to Retreatment, with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"Percentage of Retreated Subjects With a Change ≥ 0.3 From Baseline in HAQ-DI at Week 48","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}